Log in

NASDAQ:AYTU - Aytu Bioscience Stock Price, Forecast & News

$0.82
-0.05 (-5.75 %)
(As of 01/23/2020 09:24 AM ET)
Add
Compare
Today's Range
$0.81
Now: $0.82▼
$0.95
50-Day Range
$0.67
MA: $0.87▼
$1.05
52-Week Range
$0.65
Now: $0.82▼
$2.61
Volume259,963 shs
Average Volume127,399 shs
Market Capitalization$17.00 million
P/E RatioN/A
Dividend YieldN/A
Beta4.61
Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AYTU
Previous Symbol
CUSIPN/A
CIKN/A
Webhttp://aytubio.com/
Phone720-437-6580

Debt

Debt-to-Equity RatioN/A
Current Ratio1.96
Quick Ratio1.74

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$7.32 million
Price / Sales2.32
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.43 per share
Price / Book1.91

Profitability

EPS (Most Recent Fiscal Year)($3.48)
Net Income$-27,130,000.00
Net Margins-390.43%
Return on Equity-252.42%
Return on Assets-78.14%

Miscellaneous

Employees52
Outstanding Shares20,730,000
Market Cap$17.00 million
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable

Receive AYTU News and Ratings via Email

Sign-up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:AYTU Rates by TradingView

(Ad)

One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions

What is Aytu Bioscience's stock symbol?

Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."

When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?

Aytu Bioscience's stock reverse split on the morning of Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.

How were Aytu Bioscience's earnings last quarter?

Aytu Bioscience Inc (NASDAQ:AYTU) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.02. The firm had revenue of $1.44 million for the quarter, compared to the consensus estimate of $1.45 million. Aytu Bioscience had a negative net margin of 390.43% and a negative return on equity of 252.42%. View Aytu Bioscience's Earnings History.

When is Aytu Bioscience's next earnings date?

Aytu Bioscience is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Aytu Bioscience.

What price target have analysts set for AYTU?

1 equities research analysts have issued twelve-month price objectives for Aytu Bioscience's shares. Their forecasts range from $4.75 to $5.00. On average, they anticipate Aytu Bioscience's share price to reach $4.88 in the next year. This suggests a possible upside of 494.5% from the stock's current price. View Analyst Price Targets for Aytu Bioscience.

What is the consensus analysts' recommendation for Aytu Bioscience?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aytu Bioscience.

What are Wall Street analysts saying about Aytu Bioscience stock?

Here are some recent quotes from research analysts about Aytu Bioscience stock:
  • 1. According to Zacks Investment Research, "Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. " (1/15/2020)
  • 2. Northland Securities analysts commented, "We perceive the co-promotion agreement positively as significantly enhances direct selling of Natesto while placing a higher promotional focus on urologists and endocrinologists. Pre-open, Aytu BioScience announced that it amended its agreement with Acerus Pharmaceuticals, wherein Natesto (testosterone nasal gel spray for the treatment of Low-T) will be co-promoted with Acerus Pharamceuticals. Under the terms of the amended agreement and upon closing, Acerus Pharmaceuticals will launch a complementary US commercial team of at least 25 US-based specialty sales reps that will market Natesto directly to urologists and endocrinologists. This will nearly double the size of the Natesto field salesforce." (7/30/2019)

Has Aytu Bioscience been receiving favorable news coverage?

Media headlines about AYTU stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aytu Bioscience earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Aytu Bioscience.

Are investors shorting Aytu Bioscience?

Aytu Bioscience saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 735,800 shares, an increase of 75.1% from the December 15th total of 420,100 shares. Based on an average daily trading volume, of 125,500 shares, the short-interest ratio is currently 5.9 days. Approximately 4.5% of the company's stock are short sold. View Aytu Bioscience's Current Options Chain.

Who are some of Aytu Bioscience's key competitors?

What other stocks do shareholders of Aytu Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu Bioscience investors own include Corbus Pharmaceuticals (CRBP), Axsome Therapeutics (AXSM), Inovio Pharmaceuticals (INO), Achieve Life Sciences (ACHV), Verastem (VSTM), Akers Biosciences (AKER), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), SCYNEXIS (SCYX) and NIO (NIO).

Who are Aytu Bioscience's key executives?

Aytu Bioscience's management team includes the folowing people:
  • Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
  • Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
  • Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)

Who are Aytu Bioscience's major shareholders?

Aytu Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include Searle & CO. (1.31%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green, Jarrett Disbrow and Joshua R Disbrow. View Institutional Ownership Trends for Aytu Bioscience.

Which major investors are buying Aytu Bioscience stock?

AYTU stock was bought by a variety of institutional investors in the last quarter, including Searle & CO.. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, David A Green, Jarrett Disbrow and Joshua R Disbrow. View Insider Buying and Selling for Aytu Bioscience.

How do I buy shares of Aytu Bioscience?

Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aytu Bioscience's stock price today?

One share of AYTU stock can currently be purchased for approximately $0.82.

How big of a company is Aytu Bioscience?

Aytu Bioscience has a market capitalization of $17.00 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.View Additional Information About Aytu Bioscience.

What is Aytu Bioscience's official website?

The official website for Aytu Bioscience is http://aytubio.com/.

How can I contact Aytu Bioscience?

Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]om.


MarketBeat Community Rating for Aytu Bioscience (NASDAQ AYTU)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  203 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  413
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: Quiet Period
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel